Literature DB >> 17306935

Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma.

Eric L Chang1, Serap Akyurek, Tedde Avalos, Neal Rebueno, Chris Spicer, John Garcia, Robin Famiglietti, Pamela K Allen, K S Clifford Chao, Anita Mahajan, Shiao Y Woo, Moshe H Maor.   

Abstract

PURPOSE: To evaluate the spatial relationship between peritumoral edema and recurrence pattern in patients with glioblastoma (GBM). METHODS AND MATERIALS: Forty-eight primary GBM patients received three-dimensional conformal radiotherapy that did not intentionally include peritumoral edema within the clinical target volume between July 2000 and June 2001. All 48 patients have subsequently recurred, and their original treatment planning parameters were used for this study. New theoretical radiation treatment plans were created for the same 48 patients, based on Radiation Therapy Oncology Group (RTOG) target delineation guidelines that specify inclusion of peritumoral edema. Target volume and recurrent tumor coverage, as well as percent volume of normal brain irradiated, were assessed for both methods of target delineation using dose-volume histograms.
RESULTS: A comparison between the location of recurrent tumor and peritumoral edema volumes from all 48 cases failed to show correlation by linear regression modeling (r(2) = 0.0007; p = 0.3). For patients with edema >75 cm(3), the percent volume of brain irradiated to 46 Gy was significantly greater in treatment plans that intentionally included peritumoral edema compared with those that did not (38% vs. 31%; p = 0.003). The pattern of failure was identical between the two sets of plans (40 central, 3 in-field, 3 marginal, and 2 distant recurrence).
CONCLUSION: Clinical target volume delineation based on a 2-cm margin rather than on peritumoral edema did not seem to alter the central pattern of failure for patients with GBM. For patients with peritumoral edema >75 cm(3), using a constant 2-cm margin resulted in a smaller median percent volume of brain being irradiated to 30 Gy, 46 Gy, and 50 Gy compared with corresponding theoretical RTOG plans that deliberately included peritumoral edema.

Entities:  

Mesh:

Year:  2007        PMID: 17306935     DOI: 10.1016/j.ijrobp.2006.12.009

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  80 in total

1.  Clinical target volume delineation in glioblastomas: pre-operative versus post-operative/pre-radiotherapy MRI.

Authors:  P Farace; M G Giri; G Meliadò; D Amelio; L Widesott; G K Ricciardi; S Dall'Oglio; A Rizzotti; A Sbarbati; A Beltramello; S Maluta; M Amichetti
Journal:  Br J Radiol       Date:  2010-11-02       Impact factor: 3.039

2.  A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.

Authors:  Mizuhiko Terasaki; Tomoko Eto; Shinji Nakashima; Yosuke Okada; Etsuyo Ogo; Yasuo Sugita; Takashi Tokutomi; Minoru Shigemori
Journal:  J Neurooncol       Date:  2010-07-17       Impact factor: 4.130

3.  Pattern analysis of dynamic susceptibility contrast-enhanced MR imaging demonstrates peritumoral tissue heterogeneity.

Authors:  Hamed Akbari; Luke Macyszyn; Xiao Da; Ronald L Wolf; Michel Bilello; Ragini Verma; Donald M O'Rourke; Christos Davatzikos
Journal:  Radiology       Date:  2014-06-19       Impact factor: 11.105

4.  Volumetric spectroscopic imaging of glioblastoma multiforme radiation treatment volumes.

Authors:  N Andres Parra; Andrew A Maudsley; Rakesh K Gupta; Fazilat Ishkanian; Kris Huang; Gail R Walker; Kyle Padgett; Bhaswati Roy; Joseph Panoff; Arnold Markoe; Radka Stoyanova
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-24       Impact factor: 7.038

5.  Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.

Authors:  Andrew Elson; Eric Paulson; Joseph Bovi; Malika Siker; Chris Schultz; Peter S Laviolette
Journal:  J Neurooncol       Date:  2015-04-17       Impact factor: 4.130

6.  Corticospinal tract-sparing intensity-modulated radiotherapy treatment planning.

Authors:  Hiroshi Igaki; Akira Sakumi; Akitake Mukasa; Kuniaki Saito; Akira Kunimatsu; Yoshitaka Masutani; Shunya Hanakita; Kenji Ino; Akihiro Haga; Keiichi Nakagawa; Kuni Ohtomo
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-15

7.  Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.

Authors:  J Sherriff; J Tamangani; L Senthil; G Cruickshank; D Spooner; B Jones; C Brookes; P Sanghera
Journal:  Br J Radiol       Date:  2013-02       Impact factor: 3.039

Review 8.  MRI-only treatment planning: benefits and challenges.

Authors:  Amir M Owrangi; Peter B Greer; Carri K Glide-Hurst
Journal:  Phys Med Biol       Date:  2018-02-26       Impact factor: 3.609

9.  Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy.

Authors:  Jochen Tuettenberg; Rainer Grobholz; Marcel Seiz; Marc A Brockmann; Frank Lohr; Frederik Wenz; Peter Vajkoczy
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-10       Impact factor: 4.553

10.  Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison.

Authors:  Marc D Piroth; Michael Pinkawa; Richard Holy; Gabriele Stoffels; Cengiz Demirel; Charbel Attieh; Hans J Kaiser; Karl J Langen; Michael J Eble
Journal:  Radiat Oncol       Date:  2009-11-23       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.